Clinical trials: Tumor Patients
Hepatocellular Carcinoma (HCC)
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
This Phase 3 study was a global, multicenter trial that randomly assigned participants to either tislelizumab or sorafenib as a first-line treatment for adults with advanced liver cancer (hepatocellular carcinoma) that could not…
- Trial name
- NCT03412773
- Testing
- Tislelizumab, Sorafenib
- Where
- 122 sites in United States, China and 9 more
- Volunteers
- 684 people
- Sponsor
- BeiGene
Thrombosis, Venous
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).
- Trial name
- NCT00312013
- Testing
- Nadroparin
- Where
- 95 sites in Belgium, Canada and 9 more
- Volunteers
- 503 people
- Sponsor
- GlaxoSmithKline
Gastric Cancer, Gastroesophageal Junction Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer
This is a single-arm, multi-center phase II clinical study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With advanced gastric cancer or gastroesophageal junction cancer.
- Trial name
- NCT05395780
- Testing
- MAX-40279
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Maxinovel Pty., Ltd.
High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion
Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities
The goal of this clinical trial is to learn if an investigational vaginal suppository therapy works to treat low-grade cervical lesions (ASC-US and LSIL) associated with high-risk human papillomavirus (hr-HPV) infection in women.
- Conditions
- High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion, ASC-US, HPV Infection
- Trial name
- NCT07572396
- Testing
- EGCG and Quinine Sulfate Vaginal Suppository
- Where
- Hong Kong
- Volunteers
- 45 people
- Sponsor
- Amplexd Therapeutics, Inc.
Prostate Cancer
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
The primary objectives of the study are to determine the safety and activity of multiple doses of MDX-010 in patients with hormone-refractory prostate cancer (HRPC), and to determine the safety and activity profile of a single…
- Trial name
- NCT00050596
- Testing
- MDX-010 / MDX-010 + Docetaxel
- Where
- 11 sites in United States
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult…
- Conditions
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
- Trial name
- NCT07361562
- Testing
- CGT4255
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cogent Biosciences, Inc.
Metastatic Breast Cancer, Locally Advanced Breast Cancer
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable locally advanced breast cancer…
- Trial name
- NCT02595762
- Where
- 12 sites in Cyprus, Greece
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Nsclc
A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction
This trial was to evaluate the efficacy of intratumoral PTS injection in alleviating airway obstruction and dyspnea by improving the percentage of lumen patency of patients with central air way NSCLC tumor severe obstruction.
- Trial name
- NCT03448146
- Testing
- Para-Toluenesulfonamide
- Where
- China
- Volunteers
- 90 people
- Sponsor
- PTS International Inc.
Advanced Prostate Cancer
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT07115446
- Testing
- HS-20093, HRS-5041
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Hansoh BioMedical R&D Company
Central Nervous System Diseases, Central Nervous System Neoplasms
Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs
Safety and Efficacy Study in pediatric subjects <2 years of age who have undergone Brain or Spine MRI pre and post 0.1 mmol/kg ProHance administration. Imaging conditions will represent those in routine clinical practice.
- Trial name
- NCT03750188
- Testing
- ProHance
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Bracco Diagnostics, Inc
Breast Cancer
Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
The increasing use of anthracyclines and taxanes in the adjuvant, neoadjuvant and first-line metastatic settings, led to a raise of patients presenting with metastatic breast cancer after treatment with these agents.
- Trial name
- NCT01095003
- Testing
- Vinflunine plus Capecitabine, Capecitabine
- Where
- 110 sites in Argentina, Belarus and 19 more
- Volunteers
- 770 people
- Sponsor
- Pierre Fabre Medicament
Solid Cancers
A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase Ib, open-label, dose-escalation study of MNRP1685A given by intravenous (IV) infusion as therapy for locally advanced or metastatic solid tumors.
- Trial name
- NCT00954642
- Testing
- bevacizumab, MNRP1685A, paclitaxel
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Thymic Tumors
A Study of KC1036 in Patients with Advanced Thymic Tumors
This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.
- Trial name
- NCT05683886
- Testing
- KC1036
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Advanced Cancer
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
The purpose of this study is to compare an injectable emulsion form of docetaxel to Taxotere in patients with advanced cancer.
- Trial name
- NCT00664170
- Testing
- ANX-514, docetaxel
- Where
- 13 sites in United States, Argentina and 1 more
- Volunteers
- 39 people
- Sponsor
- Mast Therapeutics, Inc.
Pancreatic Cancer
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
This study will compare the efficacy and safety of escalating versus standard doses to rash of Tarceva, in combination with gemcitabine, in patients with metastatic pancreatic cancer.
- Trial name
- NCT00652366
- Testing
- Erlotinib, escalating dose, Erlotinib, standard dose, Gemcitabine
- Where
- 89 sites in Argentina, Australia and 21 more
- Volunteers
- 467 people
- Sponsor
- Hoffmann-La Roche
Radiodermatitis
Topical Use of Difinsa53™ to Prevent Radiation Dermatitis
Phase II trial of the silibin containing cream, Difinsa53 to determine efficacy in delaying, ameliorating, or preventing radiation dermatitis in patients with breast cancer undergoing whole breast radiation.
- Trial name
- NCT02534129
- Testing
- Difinsa53, Aquaphor
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- ProTechSure Scientific, Inc.
Solid Tumors
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer…
- Trial name
- NCT07415031
- Testing
- Adagrasib, Pembrolizumab, Cetuximab
- Where
- 101 sites in United States, Australia and 19 more
- Volunteers
- 170 people
- Sponsor
- Mirati Therapeutics Inc.
Gastric Cancer, Gastroesophageal Junction Cancer
GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study)
This is a prospective, non-interventional, observational, multicentre study evaluating the real-world effectiveness and safety of AstraZeneca-developed and approved medicines used to treat gastric and/or oesophageal cancers in…
- Trial name
- GRACE-DE (NCT07882212)
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Recurrent Head and Neck Squamous Cell Carcinoma
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases.
- Trial name
- ECLIPSE (NCT06699212)
- Testing
- ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin
- Where
- 22 sites in United States, Japan and 1 more
- Volunteers
- 412 people
- Sponsor
- Rakuten Medical, Inc.
Medullary Thyroid Carcinoma
A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)
This is a single-arm, open-label, multicenter study designed to evaluate the preliminary antineoplastic activity, safety and tolerability of HA121-28 tablets administered orally in patients with medullary thyroid cancer (MTC).
- Trial name
- NCT04787328
- Testing
- HA121-28 tablets
- Where
- 13 sites in China
- Volunteers
- 30 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.